ASCENDIS PHARMA ENCOCRINOLOGY DIV A/S
BiotechASCENDIS PHARMA ENCOCRINOLOGY DIV A/S is a biotechnology company with 1 FDA-approved products.
FDA Novel Drug Designations
(2021)See 1 novel approval →
ASCENDIS PHARMA ENCOCRINOLOGY DIV A/S's Key Drugs
ASCENDIS PHARMA ENCOCRINOLOGY DIV A/S's core commercial portfolio centers on SKYTROFA — its most strategically important drugs approved in the last 15 years.
ASCENDIS PHARMA ENCOCRINOLOGY DIV A/S's Recent FDA Approvals
New NDA/BLA approvals for ASCENDIS PHARMA ENCOCRINOLOGY DIV A/S over the last two years — novel drugs only, excluding generics and label supplements.
ASCENDIS PHARMA ENCOCRINOLOGY DIV A/S's Therapeutic Areas
Disease areas where ASCENDIS PHARMA ENCOCRINOLOGY DIV A/S has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ASCENDIS PHARMA ENCOCRINOLOGY DIV A/S Pipeline Snapshot
Active clinical trials for ASCENDIS PHARMA ENCOCRINOLOGY DIV A/S across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • SKYTROFA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2021-08-25
- Latest
- 2025-07-25
- Applications
- 1